{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:23:13Z","timestamp":1765423393940,"version":"3.41.2"},"reference-count":36,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1136\/ijgc-2022-004028","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T10:00:47Z","timestamp":1675936847000},"page":"929-936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601"],"prefix":"10.1016","volume":"33","clinical-trial-number":[{"clinical-trial-number":"nct03161132","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3568-4345","authenticated-orcid":false,"given":"Jos\u00e9 Alejandro","family":"Perez-Fidalgo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Iglesias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Hern\u00e1ndez-Sosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Purificaci\u00f3n","family":"Estevez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Manso S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Santaballa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3592-7194","authenticated-orcid":false,"given":"Ana","family":"Oaknin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Redondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M Jes\u00fas","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gonz\u00e1lez-Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2022-004028_bb0010","first-page":"E174","article-title":"Worldwide incidence and mortality of ovarian cancer and human development index (HDI): GLOBOCAN sources and methods 2018","volume":"62","author":"Khazaei","year":"2021","journal-title":"J Prev Med Hyg"},{"key":"10.1136\/ijgc-2022-004028_bb0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004028_bb0020","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004028_bb0025","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.283.17.2260","article-title":"Clinicopathologic features of BRCA-linked and sporadic ovarian cancer","volume":"283","author":"Boyd","year":"2000","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2022-004028_bb0030","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2022-004028_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/proteomes10020016","article-title":"Applications of proteomics in ovarian cancer: dawn of a new era","volume":"10","author":"Ghose","year":"2022","journal-title":"Proteomes"},{"key":"10.1136\/ijgc-2022-004028_bb0040","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1158\/0008-5472.CAN-12-0324","article-title":"Clinicopathological features of homologous recombination-deficient epithelial ovarian cancers: sensitivity to PARP inhibitors, platinum, and survival","volume":"72","author":"Mukhopadhyay","year":"2012","journal-title":"Cancer Res"},{"key":"10.1136\/ijgc-2022-004028_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/genes9120629","article-title":"RAD-ical new insights into RAD51 regulation","volume":"9","author":"Sullivan","year":"2018","journal-title":"Genes (Basel)"},{"key":"10.1136\/ijgc-2022-004028_bb0050","doi-asserted-by":"crossref","first-page":"47154","DOI":"10.18632\/oncotarget.17005","article-title":"Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1\/2 mutated patients with advanced ovarian cancer","volume":"8","author":"Rafii","year":"2017","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2022-004028_bb0055","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","article-title":"Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial","volume":"17","author":"Ledermann","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2022-004028_bb0060","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"Del Campo","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2022-004028_bb0065","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"10.1136\/ijgc-2022-004028_bb0070","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/annonc\/mdw238","article-title":"Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial","volume":"27","author":"Lindemann","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004028_bb0075","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1158\/1078-0432.CCR-20-0054","article-title":"CA-125 elimination rate constant K (KELIM) is a marker of chemosensitivity in patients with ovarian cancer: results from the phase II CHIVA trial","volume":"26","author":"You","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2022-004028_bb0080","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-020-00661-4","article-title":"Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy","volume":"13","author":"Henriksen","year":"2020","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2022-004028_bb0085","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-75316-x","article-title":"Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study","volume":"10","author":"Farolfi","year":"2020","journal-title":"Sci Rep"},{"key":"10.1136\/ijgc-2022-004028_bb0090","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/annonc\/mds494","article-title":"A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG","volume":"24","author":"Banerjee","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2022-004028_bb0095","doi-asserted-by":"crossref","DOI":"10.1186\/s13048-019-0527-z","article-title":"Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a meta-analysis","volume":"12","author":"Gong","year":"2019","journal-title":"J Ovarian Res"},{"key":"10.1136\/ijgc-2022-004028_bb0100","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000015876","article-title":"Prognostic value of lymphocyte-to-monocyte ratio in ovarian cancer: a meta-analysis","volume":"98","author":"Lu","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1136\/ijgc-2022-004028_bb0105","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.7150\/jca.42477","article-title":"Combined preoperative LMR and CA125 for prognostic assessment of ovarian cancer","volume":"11","author":"Tang","year":"2020","journal-title":"J Cancer"},{"key":"10.1136\/ijgc-2022-004028_bb0110","doi-asserted-by":"crossref","DOI":"10.1111\/eci.12917","article-title":"Prognostic significance of platelet-to-lymphocyte ratio in patients with ovarian cancer: a meta-analysis","volume":"48","author":"Tian","year":"2018","journal-title":"Eur J Clin Invest"},{"key":"10.1136\/ijgc-2022-004028_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100212","article-title":"Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)","volume":"6","author":"Perez-Fidalgo","year":"2021","journal-title":"ESMO Open"},{"issue":"15_suppl","key":"10.1136\/ijgc-2022-004028_bb0120","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1200\/JCO.2021.39.15_suppl.5549","article-title":"Health-related quality of life (QOL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601)","volume":"39","author":"Perez-Fidalgo","year":"2021","journal-title":"JCO"},{"key":"10.1136\/ijgc-2022-004028_bb0125","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2016-000038","article-title":"Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis","volume":"1","author":"Orditura","year":"2016","journal-title":"ESMO Open"},{"key":"10.1136\/ijgc-2022-004028_bb0130","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2147\/CMAR.S234618","article-title":"Prognosis value of platelet counts, albumin and neutrophil-lymphocyte ratio of locoregional recurrence in patients with operable head and neck squamous cell carcinoma","volume":"12","author":"Ye","year":"2020","journal-title":"Cancer Manag Res"},{"key":"10.1136\/ijgc-2022-004028_bb0135","article-title":"Pretreatment neutrophil-to-lymphocyte ratio: a prognostic biomarker of survival in patients with epithelial ovarian cancer","volume":"13","author":"John-Olabode","year":"2021","journal-title":"Cureus"},{"key":"10.1136\/ijgc-2022-004028_bb0140","doi-asserted-by":"crossref","first-page":"737","DOI":"10.7150\/jca.17668","article-title":"Peripheral blood lymphocyte-to-monocyte ratio as a prognostic factor in advanced epithelial ovarian cancer: a multicenter retrospective study","volume":"8","author":"Zhu","year":"2017","journal-title":"J Cancer"},{"key":"10.1136\/ijgc-2022-004028_bb0145","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-004028_bb0150","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonz\u00e1lez-Mart\u00edn","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2022-004028_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163888","article-title":"BRCA mutations in ovarian and prostate cancer: bench to bedside","volume":"14","author":"Boussios","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1136\/ijgc-2022-004028_bb0160","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-20935-9","article-title":"Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors","volume":"12","author":"Valero","year":"2021","journal-title":"Nat Commun"},{"key":"10.1136\/ijgc-2022-004028_bb0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ygyno.2018.05.004","article-title":"Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients","volume":"150","author":"Baert","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2022-004028_bb0170","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.smim.2016.03.018","article-title":"Human neutrophils: their role in cancer and relation to myeloid-derived suppressor cells","volume":"28","author":"Moses","year":"2016","journal-title":"Semin Immunol"},{"key":"10.1136\/ijgc-2022-004028_bb0175","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1084\/jem.20181170","article-title":"Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum","volume":"216","author":"Lee","year":"2019","journal-title":"J Exp Med"},{"key":"10.1136\/ijgc-2022-004028_bb0180","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s12094-011-0687-9","article-title":"Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer","volume":"13","author":"Asher","year":"2011","journal-title":"Clin Transl Oncol"},{"key":"10.1136\/ijgc-2022-004028_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12100990","article-title":"Adjuvant antitumor immunity contributes to the overall antitumor effect of pegylated liposomal doxorubicin (Doxil\u00ae) in C26 tumor-bearing immunocompetent mice","volume":"12","author":"Takayama","year":"2020","journal-title":"Pharmaceutics"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24024599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24024599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2022-004028","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:40:13Z","timestamp":1753101613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24024599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1048891X24024599"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2022-004028","relation":{},"ISSN":["1048-891X"],"issn-type":[{"type":"print","value":"1048-891X"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and molecular signature of survival and resistance to olaparib plus pegylated liposomal doxorubicin in platinum-resistant ovarian cancer: a stratified analysis from the phase II clinical trial ROLANDO, GEICO-1601","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2022-004028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}